Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. due to a warning letter from the U.S. Food and Drug Administration regarding misleading advertising related to the company's cancer therapy [1][3]. Group 1: Investigation Details - The investigation focuses on whether ImmunityBio's executive officers may have violated federal securities laws, potentially allowing for recovery of investor losses [1][3]. - The FDA's warning letter, issued on March 24, 2026, stated that a television advertisement and podcast promoting ImmunityBio's cancer therapy were false or misleading [3]. Group 2: Investor Information - Investors who purchased ImmunityBio securities and suffered losses are encouraged to join the investigation, with no cost or obligation [2]. - Contact information for inquiries includes Jim Baker at jimb@johnsonfistel.com or (619) 814-4471 [2]. Group 3: About Johnson Fistel, PLLP - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, representing both individual and institutional investors [4]. - The firm has been recognized as a top plaintiffs' securities law firm, having recovered approximately $90.725 million for clients in previous cases [5].

Core Viewpoint - Hercules Capital, Inc. (HTGC) is facing a class action lawsuit due to allegations of misleading statements and inadequate due diligence in its deal sourcing and portfolio valuation processes, which has led to significant financial losses for investors [2][4][5]. Group 1: Lawsuit Details - The lawsuit is based on claims that during the class period from May 1, 2025, to February 27, 2026, the company made materially false and misleading statements regarding its business operations and financial health [4][5]. - Allegations include overstating the due diligence in deal sourcing and loan origination, misclassifying portfolio investments, and misrepresenting portfolio valuations [5][6]. Group 2: Impact on Stock Price - Following the publication of a report on February 27, 2026, which criticized the company's practices, Hercules Capital's stock price dropped by $1.22, or 7.9%, closing at $14.21 per share on unusually high trading volume [3]. Group 3: Company Practices - A report indicated that Hercules Capital's deal sourcing relied heavily on copying investments from Google Ventures without conducting its own due diligence [2]. - The company's valuation process was described as lacking sufficient checks, with a small team responsible for evaluating numerous companies, raising concerns about the accuracy of its reported book value [3].

Core Viewpoint - A class action lawsuit has been filed against Lufax Holding Ltd and certain officers for alleged violations of federal securities laws during the Class Period from April 7, 2023, to January 26, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Lufax securities during the specified Class Period [2]. - Allegations include that Lufax lacked adequate internal controls, certain financial results were materially misstated, and defendants' statements regarding Lufax's business and prospects were materially false and misleading [8]. Group 2: Investor Participation - Investors who suffered losses in Lufax have until May 20, 2026, to request to be appointed as lead plaintiff in the case [3]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [3]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [4]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [5].

Core Viewpoint - A class action lawsuit has been filed against Hercules Capital, Inc. and certain officers for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Hercules securities between May 1, 2025, and February 27, 2026 [2]. - The Complaint alleges that Defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's business and operations [3]. - Specific allegations include overstating due diligence in deal sourcing and loan origination, misclassifying portfolio investments, and misrepresenting portfolio valuations [8]. Group 2: Investor Participation - Investors who suffered losses in Hercules have until May 19, 2026, to request to be appointed as lead plaintiff [3]. - Participation in any recovery does not require serving as lead plaintiff [3]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [4]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [5].

Core Viewpoint - An investigation has been announced regarding Arq, Inc. (NASDAQ: ARQ) for potential violations of federal securities laws, indicating possible legal issues that may affect investors [1]. Group 1 - The Law Offices of Howard G. Smith are representing investors of Arq, Inc. who may have suffered financial losses [1]. - Investors are encouraged to contact the law firm to discuss their legal rights and potential claims for recovering losses [1].

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for allegedly misleading investors regarding its partnership with Microsoft, leading to a significant drop in stock price [1][3]. Company Overview - Richtech Robotics Inc. is headquartered in Las Vegas, Nevada, and specializes in AI-driven robotic solutions, particularly for the restaurant and hospitality industries [2]. Legal Allegations - The lawsuit claims that Richtech falsely represented its relationship with Microsoft as a "hands-on collaboration" and "joint engineering effort" during the class period from January 27 to January 29, 2026 [3]. - The truth about the nature of the relationship was revealed on January 29, 2026, when an article stated that Microsoft characterized the engagement as a "standard" customer program with "no commercial element" [3]. Stock Price Impact - Following the revelation, Richtech's stock price fell from $5.08 per share on January 28 to $4.02 per share on January 29, and further down to $3.58 per share on January 30, marking a total decline of nearly 30% [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Gemini Space Station, Inc. for alleged misrepresentations regarding the company's business and operations during its IPO and subsequent trading period [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Gemini securities between September 12, 2025, and February 17, 2026, including those who bought shares during the IPO [1]. - Defendants are accused of failing to disclose that the company overstated the viability of its core business as a crypto platform [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file papers by May 18, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [3]. Group 3: Company Background - Gemini Space Station, Inc. is publicly traded on NASDAQ under the ticker GEMI [1].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the progress of its pivotal study for Huntington's disease, leading to significant stock price fluctuations [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, specializing in gene therapies for rare and severe diseases, with its lead product candidate being AMT-130, currently in clinical trials for Huntington's disease [2]. Legal Proceedings - The lawsuit claims that uniQure misled investors about the design and progress of the pivotal study, which led to a nearly 250% spike in share prices following the announcement of positive topline results on September 24, 2025 [3]. - On November 3, 2025, uniQure disclosed that the FDA did not accept the Phase I/II study data as sufficient for a Biologics License Application (BLA) submission, resulting in a nearly 50% drop in share prices from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].

Core Viewpoint - Tennant Company is under investigation for potential violations of federal securities laws following a significant stock drop of 23% due to issues with its ERP system [1][2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Tennant Company for possible securities fraud related to misleading statements about the implementation of a large-scale ERP system [2][3]. - The investigation focuses on whether Tennant misrepresented the progress and success of the ERP rollout, claiming it was "on time and on budget" while operational disruptions occurred [3][6]. Group 2: Stock Performance - On February 24, 2026, Tennant's stock price fell from $82.30 to $63.02 per share, marking a decline of $19.28 per share, which is a 23.4% drop [4][6]. - The company reported a loss of approximately $30 million in sales due to the ERP system's rollout issues and anticipates spending over $20 million in 2026 to address these problems, significantly higher than the planned $5 million [3][4]. Group 3: Company Background - Tennant Company specializes in manufacturing industrial cleaning equipment, including mechanical floor scrubbers and sweepers used in various commercial settings [2].

Core Viewpoint - Eos Energy is facing a class action lawsuit for securities fraud due to misrepresentations regarding its revenue growth and manufacturing capabilities, which led to a significant stock drop of approximately 39% [1][2][5]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Eos Energy Enterprises, Inc. and certain senior executives for securities fraud after the company's stock dropped around 39% [2][3]. - Investors have until May 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of New Jersey [3][6]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of Eos Energy investors [3]. Group 2: Reasons for Stock Decline - Eos Energy reported a substantial net loss of approximately $970 million for fiscal year 2025 and disclosed revenue that fell short of previously stated guidance due to high operational costs and production inefficiencies [5][6]. - The company had issued revenue guidance of $150 million to $160 million for fiscal year 2025, which was deemed misleading as it faced significant production challenges [4][5]. - Following the negative disclosures, Eos Energy's stock price fell by $4.39 per share, closing at $6.74 on heavy trading volume [6].